A Phase I Clinical Trial in 18-60 Adults
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Sponsors: CanSino Biologics Inc.; Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Adenoviruses | Biotechnology | Centers for Disease Control and Prevention (CDC) | China Health | Clinical Trials | Coronavirus | COVID-19 | Hospitals | Research | Vaccines